Adding lencanizumab to standard care for early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether adding a new medicine called lencanizumab to usual Alzheimer's treatments can help people in the early stages of the disease. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have a diagnosis of early Alzheimer's disease or mild cognitive impairment (MCI) with confirmed amyloid deposits in the brain.
- You can speak Mandarin and have at least a primary school education.
- You have a caregiver or family member who can help with assessments.
- You are willing to have MRI scans and other tests.
- You do not have other serious medical conditions that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
This study tests a new treatment, called X/T, for people with Alzheimer's disease who are already taking lecanemab (Leqembi). The goal is to see if adding X/T is safe and tolerable, and if it might help manage symptoms.
This trial tests two medications (donanemab and RG6289) alone or together in people who carry a specific genetic mutation (PSEN1 E280A) that causes early-onset Alzheimer's disease. It aims to see if these drugs can slow or prevent memory loss.
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.